Skip to main content

Table 3 Clinical and microbiological characteristics at baseline of 50 patients with E. coli bacteremic UTI—Per-protocol population (n = 50)

From: The efficacy of pivmecillinam in oral step-down treatment in hospitalised patients with E. coli bacteremic urinary tract infection; a single-arm, uncontrolled treatment study

Baseline characteristics Result
Age, median (range), y 67 (34–87)
Women 28 (56.0)
Charlson comorbidity index—CCI, mean 1.8
 CCI < 3 39 (73.6)
 CCI > 5 4 (7.5)
Diabetes mellitus 11 (22.0)
Cancer (lymphoma/leukemia/solid tumour) 7 (13.2)
Indwelling urinary catheter 8 (15.1)
BMIa, median (range) 26.4 (16.6–38.1)
Positive blood culture on admission 50 (100.0)
Positive blood culture on day 3 1 (2.0)
E. coli as causative agent 50 (100.0)
Parenteral antibiotic day 0–3  
 Ampicillin + gentamicin 27 (54.0)
 Cefotaxime 7 (14.0)
 Piperacillin/tazobactam 0 (0.0)
 Ampicillin 1 (2.0)
 Combination of above 15 (30.0)
Q-SOFAb ≥ 2 on admission 2 (4.0)
SIRSc ≥ 3 on admission 31 (62.0)
C-reactive protein on admission, mg/L, median (range) 163 (1.8–349.0)
Procalcitonin on admission, mcg/L, median (range) 1.0 (< 0.1–56.1)
White cell count on admission, 109 × cells/L, median (range) 14.5 (4.7–137.0)
Neutrophils on admission, 109 × cells/L, median (range) 11.7 (1.9–23.1)
E-GFRd on admission, median (range) 59.5 (23–107)
Body temperature ≥ 39.0 °C 20 (40.0)
Symptoms of UTI on admissione 29 (58.0)
Microbiology Result
Positive urine culture on admission (E. coli > 103 CFUf/mL) 45 (90.0)
Non-wild type (mecillinam inhibition zone 16–19 mm) 4 (8.0)
ESBLg-producing 2 (4.0)
Resistant to ciprofloxacin 6 (12.0)
Resistant to TMP–SMXh 11 (22.0)
Resistant to gentamicin 1 (2.0)
Resistant to cefotaxime 2 (4.0)
Resistant to ampicillin 18 (36.0)
Resistant to meropenem 0 (0.0)
Resistant to piperacillin/tazobactam 3 (6.0)
  1. Data are number (%), unless otherwise indicated
  2. aBody Mass Index, bQuick Sepsis-related Organ Failure Assessment, cSystemic Inflammatory Response Syndrome, dEstimated Glomerular Filtration Rate, eOne of the following: dysuria, pollakisuria, hematuria, suprapubic pain or abdominal pain, fColony Forming Units, gExstended Spectrum Beta-Lactamases, hTrimethoprim sulfamethoxazole